Aspirin and clopidogrel resistance: methodological challenges and opportunities

Vasc Health Risk Manag. 2010 Mar 24;6:109-12. doi: 10.2147/vhrm.s9087.

Abstract

Antiplatelet drug resistance is one of the urgent issues in current cardiovascular medicine. Many platelet function tests have been used to define responsiveness of patients with cardiovascular disease to aspirin and clopidogrel. In most studies, cut-off values of platelet function tests for defining responsiveness to antiplatelets were chosen arbitrarily. Different tests provided wide-ranging figures of the prevalence of aspirin and clopidogrel resistance, suggesting poor correlation between currently available platelet function tests. Measurement of platelet size seems to be a promising approach for monitoring antiplatelet drug therapy. This commentary highlights some limitations of studies on aspirin and clopidogrel resistance in patients undergoing coronary interventions.

Keywords: aspirin; cardiovascular disease; clopidogrel; platelet function tests; resistance.

Publication types

  • Review

MeSH terms

  • Aspirin / therapeutic use*
  • Blood Platelets / drug effects
  • Cardiovascular Diseases / drug therapy*
  • Clopidogrel
  • Drug Resistance*
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Function Tests
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticlopidine
  • Aspirin